STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2026

A summary of changes in the Company’s nonvested restricted shares for the three months ended March 31, 2026 and March 31, 2025 follows:


	Shares	Weighted-Average Grant-Date Fair Value, per share
Nonvested at January 1, 2026	33,750	$	15.87

Vested	(10,065)	(16.35)

Nonvested at March 31, 2026	23,685	$	15.67


	Shares	Weighted-Average Grant-Date Fair Value, per share
Nonvested at January 1, 2025	47,485	$	14.54
Granted	20,500	15.93
Vested	(24,225)	(13.23)
Forfeited	(340)	(14.50)
Nonvested at March 31, 2025	43,420	$	15.93

A summary of the activity in the Equity Plan for the three months ended March 31, 2026 and March 31, 2025 follows:


	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2026	359,233	$	15.68


Forfeited	(24,570)	(15.34)

Outstanding at March 31, 2026	334,663	$	15.71	3.38	$	—
Vested and exercisable at March 31, 2026	334,663	$	15.71	3.38	$	—


	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2025	364,063	$	15.68

Exercised	(1,050)	(14.67)


Outstanding at March 31, 2025	363,013	$	15.68	4.40	$	34
Vested and exercisable at March 31, 2025	357,688	$	15.69	4.40	$	34